Renli Teng

4.2k total citations · 1 hit paper
63 papers, 3.3k citations indexed

About

Renli Teng is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pharmacology. According to data from OpenAlex, Renli Teng has authored 63 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Cardiology and Cardiovascular Medicine, 19 papers in Surgery and 14 papers in Pharmacology. Recurrent topics in Renli Teng's work include Antiplatelet Therapy and Cardiovascular Diseases (41 papers), Lipoproteins and Cardiovascular Health (16 papers) and Venous Thromboembolism Diagnosis and Management (14 papers). Renli Teng is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (41 papers), Lipoproteins and Cardiovascular Health (16 papers) and Venous Thromboembolism Diagnosis and Management (14 papers). Renli Teng collaborates with scholars based in United States, United Kingdom and Sweden. Renli Teng's co-authors include Kathleen Butler, Robert F. Storey, Cheryl Wei, Udaya S. Tantry, Paul A. Gurbel, Kevin P. Bliden, Mark J. Antonino, Arun Karunakaran, Shankar B. Patil and Stuart Oliver and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and European Heart Journal.

In The Last Decade

Renli Teng

61 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease

2009 794 citations Paul A. Gurbel, Kevin P. Bliden et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Renli Teng United States	27	2.6k	1.1k	1.0k	456	396	63	3.3k
Frank LaCreta United States	38	1.7k 0.6×	916 0.8×	863 0.9×	482 1.1×	1.1k 2.9×	110	4.5k
Hideo Naganuma Japan	21	1.4k 0.5×	742 0.7×	503 0.5×	356 0.8×	159 0.4×	41	2.1k
Vera H.M. Deneer Netherlands	31	1.9k 0.7×	1.1k 1.0×	505 0.5×	730 1.6×	408 1.0×	88	4.5k
Fabiana Rollini United States	29	2.2k 0.8×	1.1k 1.1×	602 0.6×	142 0.3×	315 0.8×	112	2.5k
David S. Small United States	28	1.9k 0.7×	924 0.9×	526 0.5×	382 0.8×	367 0.9×	66	2.4k
Atef Halabi Germany	25	805 0.3×	306 0.3×	335 0.3×	242 0.5×	436 1.1×	79	2.2k
Guillaume Cayla France	24	2.5k 1.0×	1.3k 1.2×	475 0.5×	347 0.8×	403 1.0×	149	3.3k
Nagy A. Farid United States	30	3.0k 1.1×	1.3k 1.2×	718 0.7×	908 2.0×	669 1.7×	43	3.8k
Dagmar Kubitza Germany	38	5.0k 1.9×	645 0.6×	3.8k 3.8×	646 1.4×	38 0.1×	82	6.6k
Jochem W. van Werkum Netherlands	23	2.9k 1.1×	1.6k 1.5×	699 0.7×	409 0.9×	473 1.2×	58	3.3k

Countries citing papers authored by Renli Teng

Since Specialization

Citations

This map shows the geographic impact of Renli Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renli Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renli Teng more than expected).

Fields of papers citing papers by Renli Teng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renli Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renli Teng. The network helps show where Renli Teng may publish in the future.

Co-authorship network of co-authors of Renli Teng

This figure shows the co-authorship network connecting the top 25 collaborators of Renli Teng. A scholar is included among the top collaborators of Renli Teng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renli Teng. Renli Teng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Yingxue, Renli Teng, & Julien Ogier. (2025). Bioavailability, Metabolism, and Excretion of [¹⁴C]‐Tazemetostat in Patients With B‐Cell Lymphomas or Advanced Solid Tumors. Clinical Pharmacology in Drug Development. 14(3). 231–239. 1 indexed citations

Teng, Renli, et al.. (2018). Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. European Journal of Clinical Pharmacology. 74(9). 1141–1148. 6 indexed citations

Angiolillo, Dominick J., Francesco Franchi, Ron Waksman, et al.. (2016). Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. Journal of the American College of Cardiology. 67(6). 603–613. 35 indexed citations

Teng, Renli. (2015). Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clinical Pharmacokinetics. 54(11). 1125–1138. 112 indexed citations

Waksman, Ron, Juan Maya, Dominick J. Angiolillo, et al.. (2014). TICAGRELOR VERSUS CLOPIDOGREL IN AFRICAN AMERICAN PATIENTS WITH CORONARY ARTERY DISEASE AND DIABETES MELLITUS. Journal of the American College of Cardiology. 63(12). A211–A211. 2 indexed citations

Teng, Renli, et al.. (2014). Evaluation of the Pharmacokinetic Interaction Between Ticagrelor and Venlafaxine, a Cytochrome P-450 2D6 Substrate, in Healthy Subjects. Clinical Therapeutics. 36(9). 1217–1225. 7 indexed citations

Teng, Renli, et al.. (2014). Pharmacokinetic Interaction Study of Ticagrelor and Cyclosporine in Healthy Volunteers. Clinical Drug Investigation. 34(8). 529–536. 18 indexed citations

Teng, Renli & Kathleen Butler. (2013). Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. PubMed. 2(1). 30–39. 40 indexed citations

Teng, Renli, Pat Mitchell, & Kathleen Butler. (2012). Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. European Journal of Clinical Pharmacology. 69(3). 477–487. 53 indexed citations

10.

Teng, Renli, Juan Maya, & Kathleen Butler. (2012). Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets. 24(8). 615–624. 35 indexed citations

11.

Storey, Robert F., Kevin P. Bliden, Shankar B. Patil, et al.. (2010). Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study. Journal of the American College of Cardiology. 56(3). 185–193. 133 indexed citations

12.

Schaefer, Franz, Johan Van de Walle, Aleksandra Żurowska, et al.. (2010). Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. Journal of Hypertension. 28(5). 1083–1090. 47 indexed citations

13.

Teng, Renli & Kathleen Butler. (2010). Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. European Journal of Clinical Pharmacology. 66(5). 487–496. 162 indexed citations

14.

Gurbel, Paul A., Kevin P. Bliden, Mark J. Antonino, et al.. (2009). Abstract 5901: The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study. Circulation. 120. 3 indexed citations

15.

Sarich, Troy C., et al.. (2004). The Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor, Are Unaffected by a Single Dose of Alcohol. The Journal of Clinical Pharmacology. 44(4). 388–393. 24 indexed citations

16.

Teng, Renli, et al.. (2004). A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor. The Journal of Clinical Pharmacology. 44(9). 1063–1071. 17 indexed citations

17.

Vincent, John, et al.. (1998). The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects. The American Journal of Surgery. 176(6). 23S–26S. 12 indexed citations

18.

Vincent, John, et al.. (1998). The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects. The American Journal of Surgery. 176(6). 32S–38S. 14 indexed citations

19.

Teng, Renli, Thomas G. Tensfeldt, Theodore E. Liston, & George Foulds. (1996). Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 675(1). 53–59. 46 indexed citations

20.

Teng, Renli, Theodore E. Liston, & Stephen Harris. (1996). Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy. 37(5). 955–963. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact